𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Improving monoclonal antibodies for cancer therapy

✍ Scribed by M. K. Robinson; L. M. Weiner; G. P. Adams

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
173 KB
Volume
61
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Monoclonal antibody therapy for posttran
Monoclonal antibody therapy for posttransplant lymphoproliferative disorders
✍ Thomas M. Habermann πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

Background: Post-transplant lymphoproliferative (PT-LPD) disorder is a life-threatening complication with an incidence of 1-10%. Uniform treatment, so far, does not exist. Methods: In December 1996, five months after a liver transplant, a 43-year-old patient developed a PT-LPD with para-aortal lymph

Recombinant polyclonal antibodies for ca
Recombinant polyclonal antibodies for cancer therapy
✍ Jacqueline Sharon; Meredith A. Liebman; Brent R. Williams πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 178 KB

## Abstract Although monoclonal antibodies are increasingly used for cancer therapy, remissions are only temporary due to emergence of tumor cell escape variants that are no longer affected by the antibody. The emergence of escape variants could be minimized by multi‐targeting of tumor cells with p